Navigation

2006/031 NICE approves docetaxel as a treatment option for men with advanced prostate cancer

The National Institute for Health and Care Excellence (NICE) has today issued guidance to the NHS in England and Wales recommending the use of docetaxel as a treatment option for men with prostate cancer that has spread to other parts of their body and is no longer responding to treatment with hormonal therapies (known as hormone-refractory metastatic prostate cancer).

This page was last updated: 03 August 2007

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.